<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880723</url>
  </required_header>
  <id_info>
    <org_study_id>08-1123-01</org_study_id>
    <secondary_id>1R01HL108962-01</secondary_id>
    <nct_id>NCT01880723</nct_id>
  </id_info>
  <brief_title>Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis</brief_title>
  <official_title>Modifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ Channels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our aims were to determine if exhaled breath condensate (EBC) could detect differences in ion
      regulation between cystic fibrosis (CF) and healthy and measure the effect of the albuterol
      on EBC ions in these populations. We hypothesized EBC chloride and sodium would be lower in
      CF patients at baseline and that albuterol would decrease EBC sodium and increase EBC
      chloride.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exhaled Sodium (mmol/L)</measure>
    <time_frame>up to 90-minutes post albuterol</time_frame>
    <description>We collected exhaled breath condensate (EBC) samples, with subjects breathing on a Jaeger EcoScreen for 20 minutes. EBC samples were collected in cystic fibrosis and healthy subjects before and 30-, 60-, and 90-minutes following albuterol administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Net Exhaled Chloride</measure>
    <time_frame>baseline to 90 minutes post albuterol administration</time_frame>
    <description>The calculation of net chloride efflux was used to account for the paracellular reabsorption of Cl- that will follow the reabsorption of Na+ to maintain electroneutral ion flux. Thus, the net chloride efflux calculation used was the gross chloride concentration plus the absolute value of the percent change in sodium from baseline multiplied by the gross chloride concentration for each time point:
Net Cl- efflux - [Cl- X-min post] + (([Na+ X-min post]-[Na+Baseline])/ [Na+Baseline]) x [Cl- X-min post])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diffusion Capacity of the Lungs for Carbon Monoxide</measure>
    <time_frame>baseline, 30-, 60- and 90-minutes post albuterol administration</time_frame>
    <description>Using the rebreathe technique the diffusion capacity of the lungs for carbon monoxide and nitric oxide were measured, and this allowed for the determination of alveolar-capillary membrane conductance and pulmonary capillary blood volume. These measurements were made at baseline and 30-, 60- and 90-minutes post albuterol administration in cystic fibrosis and healthy subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion Capacity of the Lungs for Nitric Oxide</measure>
    <time_frame>baseline, 30-, 60- and 90-minutes post albuterol administration</time_frame>
    <description>Using the rebreathe technique the diffusion capacity of the lungs for carbon monoxide and nitric oxide were measured, and this allowed for the determination of alveolar-capillary membrane conductance and pulmonary capillary blood volume. These measurements were made at baseline and 30-, 60- and 90-minutes post albuterol administration in cystic fibrosis and healthy subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Oxygen Saturation</measure>
    <time_frame>baseline, 30-, 60- and 90-minutes post albuterol</time_frame>
    <description>A finger pulse oximeter allowed for the measurement of peripheral oxygen saturation at baseline, 30-, 60- and 90-minutes post albuterol in cystic fibrosis and healthy subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Albuterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline (healthy only)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>nebulized 3 ml normal saline using a Power Neb2 nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
    <description>2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer</description>
    <arm_group_label>Albuterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo saline</intervention_name>
    <description>nebulized 3mL normal saline) using a Power Neb2 nebulizer</description>
    <arm_group_label>Saline (healthy only)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subjects:

          -  no cardiovascular abnormalities

          -  not overweight BMI&gt;25

          -  18-55 years of age

        CF subjects:

          -  mild to moderate CF (FEV1&gt;40% predicted)

          -  clinically diagnosed with positive sweat test (sweat Cl-&gt;60mmol/L)

          -  10-55 years of age

          -  clinically stable

        Exclusion Criteria:

        Healthy subjects will be excluded if:

          -  If unable to consent for him/herself (cognitive impairment)

          -  Have a history or evidence of cardiovascular and/or pulmonary abnormalities.

          -  Have an abnormal 12-lead EKG

          -  Have an abnormal pulmonary function test

          -  Have a history of asthma

          -  Have a history of renal disease or estimated creatinine clearance &lt; 55ml/min

          -  Women who are pregnant or planning to become pregnant during the study

        CF subjects:

          -  If unable to consent for him/herself (cognitive impairment)

          -  Physically unable to perform exercise or breathing tests

          -  Have a history of renal disease or estimated creatinine clearance &lt; 55ml/min

          -  Women who are pregnant or planning to become pregnant during the study.

          -  Have an abnormal 12-lead EKG

          -  Cystic Fibrosis related diabetes is uncontrolled

          -  Forced Expiratory Volume after 1 second (FEV1) is less than 40% predicted

          -  Have a history of joint disease

          -  Have history of pulmonary exacerbation within the last two weeks

          -  Experienced pulmonary hemorrhage within 6 months resulting in greater than 50cc of
             blood in the sputum

          -  not currently enrolled in any other research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne J Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics- Pulmonology, Allergy and Immunology, University of Arizona, Tucson, Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cori M Daines, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics- Pulmonology, Allergy and Immunology, University of Arizona, Tucson, Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric M Snyder, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacy Practice and Science, University of Arizona, Tucson, Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanna Phan, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacy Practice and Science, University of Arizona, Tucson, Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asad Patanwalla, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacy Practice and Science, University of Arizona, Tucson, Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pharmacy Practice and Science, University of Arizona, Tucson, Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Foxx-Lupo WT, Wheatley CM, Baker SE, Cassuto NA, Delamere NA, Snyder EM. Genetic variation of the alpha subunit of the epithelial Na+ channel influences exhaled Na+ in healthy humans. Respir Physiol Neurobiol. 2011 Dec 15;179(2-3):205-11. doi: 10.1016/j.resp.2011.08.008. Epub 2011 Aug 26.</citation>
    <PMID>21889619</PMID>
  </results_reference>
  <results_reference>
    <citation>Baker SE, Wheatley CM, Cassuto NA, Foxx-Lupo WT, Sprissler R, Snyder EM. Genetic variation of αENaC influences lung diffusion during exercise in humans. Respir Physiol Neurobiol. 2011 Dec 15;179(2-3):212-8. doi: 10.1016/j.resp.2011.08.007. Epub 2011 Aug 26.</citation>
    <PMID>21893217</PMID>
  </results_reference>
  <results_reference>
    <citation>Wheatley CM, Foxx-Lupo WT, Cassuto NA, Wong EC, Daines CL, Morgan WJ, Snyder EM. Impaired lung diffusing capacity for nitric oxide and alveolar-capillary membrane conductance results in oxygen desaturation during exercise in patients with cystic fibrosis. J Cyst Fibros. 2011 Jan;10(1):45-53. doi: 10.1016/j.jcf.2010.09.006. Epub 2010 Nov 2.</citation>
    <PMID>21050829</PMID>
  </results_reference>
  <results_reference>
    <citation>Traylor BR, Wheatley CM, Skrentny TT Jr, Foxx-Lupo WT, Phan H, Patanwala AE, Morgan WJ, Daines CL, Sprissler R, Snyder EM. Influence of genetic variation of the β2-adrenergic receptor on lung diffusion in patients with cystic fibrosis. Pulm Pharmacol Ther. 2011 Oct;24(5):610-6. doi: 10.1016/j.pupt.2011.06.001. Epub 2011 Jun 15.</citation>
    <PMID>21703359</PMID>
  </results_reference>
  <results_reference>
    <citation>Snyder EM, Wong EC, Foxx-Lupo WT, Wheatley CM, Cassuto NA, Patanwala AE. Effects of an inhaled β2-agonist on cardiovascular function and sympathetic activity in healthy subjects. Pharmacotherapy. 2011 Aug;31(8):748-56. doi: 10.1592/phco.31.8.748.</citation>
    <PMID>21923601</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2013</study_first_submitted>
  <study_first_submitted_qc>June 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <results_first_submitted>May 21, 2014</results_first_submitted>
  <results_first_submitted_qc>May 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2014</results_first_posted>
  <last_update_submitted>May 21, 2014</last_update_submitted>
  <last_update_submitted_qc>May 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Courtney Wheatley</investigator_full_name>
    <investigator_title>Graduate Research Assistant</investigator_title>
  </responsible_party>
  <keyword>exhaled breath condensate</keyword>
  <keyword>diffusion capacity of the lungs for carbon monoxide and nitric oxide</keyword>
  <keyword>albuterol</keyword>
  <keyword>peripheral oxygen saturation</keyword>
  <keyword>ion regulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy</title>
          <description>Healthy control subjects</description>
        </group>
        <group group_id="P2">
          <title>Cystic Fibrosis</title>
          <description>Patients diagnosed with cystic fibrosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy</title>
          <description>Healthy Control subjects</description>
        </group>
        <group group_id="B2">
          <title>Cystic Fibrosis</title>
          <description>Patients diagnosed with cystic fibrosis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="6"/>
                    <measurement group_id="B2" value="22" spread="8"/>
                    <measurement group_id="B3" value="24" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="9"/>
                    <measurement group_id="B2" value="60" spread="9"/>
                    <measurement group_id="B3" value="62" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169" spread="8"/>
                    <measurement group_id="B2" value="166" spread="8"/>
                    <measurement group_id="B3" value="167" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m2)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="3"/>
                    <measurement group_id="B2" value="22" spread="3"/>
                    <measurement group_id="B3" value="22" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BSA (m2)</title>
          <units>m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.1"/>
                    <measurement group_id="B2" value="1.7" spread="0.2"/>
                    <measurement group_id="B3" value="1.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VO2 peak (% predicted)</title>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108" spread="35"/>
                    <measurement group_id="B2" value="54" spread="24"/>
                    <measurement group_id="B3" value="85" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exhaled Sodium (mmol/L)</title>
        <description>We collected exhaled breath condensate (EBC) samples, with subjects breathing on a Jaeger EcoScreen for 20 minutes. EBC samples were collected in cystic fibrosis and healthy subjects before and 30-, 60-, and 90-minutes following albuterol administration.</description>
        <time_frame>up to 90-minutes post albuterol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy control subjects</description>
          </group>
          <group group_id="O2">
            <title>Cystic Fibrosis</title>
            <description>Patients diagnosed with cystic fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Sodium (mmol/L)</title>
          <description>We collected exhaled breath condensate (EBC) samples, with subjects breathing on a Jaeger EcoScreen for 20 minutes. EBC samples were collected in cystic fibrosis and healthy subjects before and 30-, 60-, and 90-minutes following albuterol administration.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="1.51"/>
                    <measurement group_id="O2" value="2.24" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.58"/>
                    <measurement group_id="O2" value="2.11" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.94"/>
                    <measurement group_id="O2" value="1.73" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="1.34"/>
                    <measurement group_id="O2" value="1.86" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diffusion Capacity of the Lungs for Carbon Monoxide</title>
        <description>Using the rebreathe technique the diffusion capacity of the lungs for carbon monoxide and nitric oxide were measured, and this allowed for the determination of alveolar-capillary membrane conductance and pulmonary capillary blood volume. These measurements were made at baseline and 30-, 60- and 90-minutes post albuterol administration in cystic fibrosis and healthy subjects.</description>
        <time_frame>baseline, 30-, 60- and 90-minutes post albuterol administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy control subjects</description>
          </group>
          <group group_id="O2">
            <title>Cystic Fibrosis</title>
            <description>Patients diagnosed with cystic fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Diffusion Capacity of the Lungs for Carbon Monoxide</title>
          <description>Using the rebreathe technique the diffusion capacity of the lungs for carbon monoxide and nitric oxide were measured, and this allowed for the determination of alveolar-capillary membrane conductance and pulmonary capillary blood volume. These measurements were made at baseline and 30-, 60- and 90-minutes post albuterol administration in cystic fibrosis and healthy subjects.</description>
          <units>mL/min/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="5.8"/>
                    <measurement group_id="O2" value="17.3" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="5.3"/>
                    <measurement group_id="O2" value="17.4" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="6.2"/>
                    <measurement group_id="O2" value="17.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="5.5"/>
                    <measurement group_id="O2" value="17.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diffusion Capacity of the Lungs for Nitric Oxide</title>
        <description>Using the rebreathe technique the diffusion capacity of the lungs for carbon monoxide and nitric oxide were measured, and this allowed for the determination of alveolar-capillary membrane conductance and pulmonary capillary blood volume. These measurements were made at baseline and 30-, 60- and 90-minutes post albuterol administration in cystic fibrosis and healthy subjects.</description>
        <time_frame>baseline, 30-, 60- and 90-minutes post albuterol administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy control subjects</description>
          </group>
          <group group_id="O2">
            <title>Cystic Fibrosis</title>
            <description>Patients diagnosed with cystic fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Diffusion Capacity of the Lungs for Nitric Oxide</title>
          <description>Using the rebreathe technique the diffusion capacity of the lungs for carbon monoxide and nitric oxide were measured, and this allowed for the determination of alveolar-capillary membrane conductance and pulmonary capillary blood volume. These measurements were made at baseline and 30-, 60- and 90-minutes post albuterol administration in cystic fibrosis and healthy subjects.</description>
          <units>mL/min/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3" spread="18.9"/>
                    <measurement group_id="O2" value="55.0" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" spread="16.7"/>
                    <measurement group_id="O2" value="56.4" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="19.2"/>
                    <measurement group_id="O2" value="56.2" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="20.6"/>
                    <measurement group_id="O2" value="58.5" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Net Exhaled Chloride</title>
        <description>The calculation of net chloride efflux was used to account for the paracellular reabsorption of Cl- that will follow the reabsorption of Na+ to maintain electroneutral ion flux. Thus, the net chloride efflux calculation used was the gross chloride concentration plus the absolute value of the percent change in sodium from baseline multiplied by the gross chloride concentration for each time point:
Net Cl- efflux – [Cl- X-min post] + (([Na+ X-min post]-[Na+Baseline])/ [Na+Baseline]) x [Cl- X-min post])</description>
        <time_frame>baseline to 90 minutes post albuterol administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy control subjects</description>
          </group>
          <group group_id="O2">
            <title>Cystic Fibrosis</title>
            <description>Patients diagnosed with cystic fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Net Exhaled Chloride</title>
          <description>The calculation of net chloride efflux was used to account for the paracellular reabsorption of Cl- that will follow the reabsorption of Na+ to maintain electroneutral ion flux. Thus, the net chloride efflux calculation used was the gross chloride concentration plus the absolute value of the percent change in sodium from baseline multiplied by the gross chloride concentration for each time point:
Net Cl- efflux – [Cl- X-min post] + (([Na+ X-min post]-[Na+Baseline])/ [Na+Baseline]) x [Cl- X-min post])</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" spread="0.05"/>
                    <measurement group_id="O2" value="0.037" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.078" spread="0.143"/>
                    <measurement group_id="O2" value="0.048" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.084" spread="0.073"/>
                    <measurement group_id="O2" value="0.057" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.077" spread="0.06"/>
                    <measurement group_id="O2" value="0.050" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Oxygen Saturation</title>
        <description>A finger pulse oximeter allowed for the measurement of peripheral oxygen saturation at baseline, 30-, 60- and 90-minutes post albuterol in cystic fibrosis and healthy subjects.</description>
        <time_frame>baseline, 30-, 60- and 90-minutes post albuterol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy control subjects</description>
          </group>
          <group group_id="O2">
            <title>Cystic Fibrosis</title>
            <description>Patients diagnosed with cystic fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Oxygen Saturation</title>
          <description>A finger pulse oximeter allowed for the measurement of peripheral oxygen saturation at baseline, 30-, 60- and 90-minutes post albuterol in cystic fibrosis and healthy subjects.</description>
          <units>percent of oxygenated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" spread="1"/>
                    <measurement group_id="O2" value="98" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="0"/>
                    <measurement group_id="O2" value="98" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" spread="1"/>
                    <measurement group_id="O2" value="98" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" spread="1"/>
                    <measurement group_id="O2" value="99" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within the study visit (~2 hours)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy</title>
          <description>Healthy control subjects</description>
        </group>
        <group group_id="E2">
          <title>Cystic Fibrosis</title>
          <description>Patients diagnosed with cystic fibrosis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Courtney Wheatley</name_or_title>
      <organization>University of Arizona</organization>
      <phone>507-266-2696</phone>
      <email>wheatley.courtney@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

